We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.00 | -0.12% | 12,156.00 | 12,126.00 | 12,128.00 | 12,258.00 | 12,114.00 | 12,114.00 | 1,961,685 | 16:35:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.62 | 188.29B |
From May 2019 to May 2024
By Micah Maidenberg
AstraZeneca PLC (AZN) said regulators in the U.S. will consider extending uses of its drug Farxiga.
The company said Monday the U.S. Food and Drug Administration accepted a supplemental new-drug application for Farxiga, agreeing to conduct a priority review of the therapy.
Regulators, in the new review, will consider the drug's use to treat patients facing the risk of cardiovascular death or the worsening of heart failure in some patients.
Adults with type two diabetes treat that disease with Farxiga, according to a website for the drug.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
January 06, 2020 07:36 ET (12:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
